NCT00903253View on ClinicalTrials.gov

A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Healthy Elderly Volunteers
Interventions
DRUG

LNK-754

Trial Locations (1)

78759

CEDRA Clinical Research, Austin

Sponsors
All Listed Sponsors
lead

Link Medicine Corporation

INDUSTRY

NCT00903253 - A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers | Biotech Hunter | Biotech Hunter